{"transactions":[{"id":704004,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-23T22:52:47.000Z","date":"2026-07-22","kind":"grant","planned":false,"acquired":true,"shares":30500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in substantially equal yearly installments beginning on the first anniversary of the grant date such that the stock options shall be fully vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":30500,"derivative":{"exercise_price":2.17,"expiration_date":"2036-07-22","underlying":"Common Stock","underlying_shares":30500},"source":{"system":"sec-edgar","filing":"0001965585-26-000006","document":"wk-form4_1784847165.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000196558526000006/wk-form4_1784847165.xml","form_type":"4"}},{"id":711843,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":31223,"kind":"person","name":"Brannan Stephen K.","position":1,"cik":"0001777631","reported_name":"Brannan Stephen K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-09T16:05:12.000Z","date":"2026-07-07","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":2.03,"value":2030.0,"ownership":{"direct":true},"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001777631-26-000007","document":"wk-form4_1783613110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777631/000177763126000007/wk-form4_1783613110.xml","form_type":"4"}},{"id":730531,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2026-06-22T23:15:02.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":96525,"price":2.25,"value":217181.25,"ownership":{"direct":false,"nature":"The Jay Venkatesan Legacy Trust"},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":5.18,"exercise_date":"2025-04-08","underlying":"Common Stock, $0.0001 par value","underlying_shares":222222},"source":{"system":"sec-edgar","filing":"0001413350-26-000004","document":"wk-form4_1782170099.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000141335026000004/wk-form4_1782170099.xml","form_type":"4"}},{"id":730530,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-22T23:15:02.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":15250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":15250,"derivative":{"exercise_price":1.98,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":15250},"source":{"system":"sec-edgar","filing":"0001413350-26-000004","document":"wk-form4_1782170099.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000141335026000004/wk-form4_1782170099.xml","form_type":"4"}},{"id":730529,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T23:15:02.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":true,"shares":224152,"price":2.25,"value":504342.0,"ownership":{"direct":false,"nature":"The Jay Venkatesan Legacy Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Prefered Stock (\"Series A Preferred\") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 96,525 shares of Series A Preferred that were converted into 222,222 shares of Common Stock and 1,930 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, thereby triggering the automatic conversion of the Series A Preferred into common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The share ownership amount has been adjusted to correct an administrative error in a prior Form 4 filed by the Reporting Person, which inadvertently reported 7,553 shares as direct ownership, rather than indirect ownership."}],"balance_after":231705,"source":{"system":"sec-edgar","filing":"0001413350-26-000004","document":"wk-form4_1782170099.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000141335026000004/wk-form4_1782170099.xml","form_type":"4"}},{"id":730528,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T23:15:02.000Z","date":"2026-05-22","kind":"purchase","planned":false,"acquired":true,"shares":589,"price":1.78,"value":1048.42,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The share ownership amount has been adjusted to correct an administrative error in a prior Form 4 filed by the Reporting Person, which inadvertently reported 7,553 shares as direct ownership, rather than indirect ownership."}],"balance_after":589,"source":{"system":"sec-edgar","filing":"0001413350-26-000004","document":"wk-form4_1782170099.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000141335026000004/wk-form4_1782170099.xml","form_type":"4"}},{"id":730525,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":36340,"kind":"person","name":"Bailey Gregory","position":1,"cik":"0001329505","reported_name":"Bailey Gregory","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2026-06-22T23:14:29.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":false,"shares":762548,"price":2.25,"value":1715733.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":5.18,"exercise_date":"2025-04-08","underlying":"Common Stock, $0.0001 par value","underlying_shares":1755555},"source":{"system":"sec-edgar","filing":"0001329505-26-000007","document":"wk-form4_1782170066.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000132950526000007/wk-form4_1782170066.xml","form_type":"4"}},{"id":730524,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":36340,"kind":"person","name":"Bailey Gregory","position":1,"cik":"0001329505","reported_name":"Bailey Gregory","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Redeemable Warrants","published_at":"2026-06-22T23:14:29.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":3333333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Issued pursuant to the same Securities Purchase Agreement dated March 17, 2026, covering 50% of the shares underlying the Pre-Funded Warrants acquired by the reporting person. The Company may call the warrants at $0.01 per underlying share upon 30 days' notice if the Common Stock closing price equals or exceeds $10.00 on the business day prior to the redemption notice, on the earlier of (i) 30 days after first patient dosing in Cohort 2 of the Company's SER-252 Phase 1b SAD study or (ii) September 30, 2026. Holders have 30 days to exercise following a call notice."}],"balance_after":3333333,"derivative":{"exercise_price":5,"exercise_date":"2026-09-17","expiration_date":"2030-03-17","underlying":"Common Stock","underlying_shares":3333333},"source":{"system":"sec-edgar","filing":"0001329505-26-000007","document":"wk-form4_1782170066.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000132950526000007/wk-form4_1782170066.xml","form_type":"4"}},{"id":730523,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":36340,"kind":"person","name":"Bailey Gregory","position":1,"cik":"0001329505","reported_name":"Bailey Gregory","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-22T23:14:29.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":15250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":15250,"derivative":{"exercise_price":1.98,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":15250},"source":{"system":"sec-edgar","filing":"0001329505-26-000007","document":"wk-form4_1782170066.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000132950526000007/wk-form4_1782170066.xml","form_type":"4"}},{"id":730522,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":36340,"kind":"person","name":"Bailey Gregory","position":1,"cik":"0001329505","reported_name":"Bailey Gregory","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T23:14:29.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":true,"shares":6666667,"price":2.2499,"value":14999334.0833,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Issued pursuant to a Securities Purchase Agreement dated March 17, 2026, at a purchase price of $2.2499 per pre-funded warrant (reflecting a $0.0001 exercise price). The Pre-Funded Warrants have no expiration date and are subject to customary beneficial ownership limitations. The exercise price and share count are subject to adjustment for stock splits, dividends, and similar events. Under NYSE American rules, issuance of the underlying shares to the reporting person is subject to prior stockholder approval which was obtained on June 17, 2026, thereby triggering the automatic conversion of the Pre-Funded Warrants into common stock."}],"balance_after":8564382,"source":{"system":"sec-edgar","filing":"0001329505-26-000007","document":"wk-form4_1782170066.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000132950526000007/wk-form4_1782170066.xml","form_type":"4"}},{"id":730521,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":36340,"kind":"person","name":"Bailey Gregory","position":1,"cik":"0001329505","reported_name":"Bailey Gregory","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T23:14:29.000Z","date":"2026-06-17","kind":"exercise","planned":false,"acquired":true,"shares":1770805,"price":2.25,"value":3984311.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Preferred Stock (\"Series A Preferred\") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 762,548 shares of Series A Preferred that were converted into 1,755,555 shares of Common Stock and 15,250 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, and the underlying Common Stock shares were issued on June 17, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The share ownership amount has been updated to reflect the correct number of shares beneficially owned by the Reporting Person."}],"balance_after":1897445,"source":{"system":"sec-edgar","filing":"0001329505-26-000007","document":"wk-form4_1782170066.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000132950526000007/wk-form4_1782170066.xml","form_type":"4"}},{"id":730540,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":31223,"kind":"person","name":"Brannan Stephen K.","position":1,"cik":"0001777631","reported_name":"Brannan Stephen K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-22T23:13:50.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":15250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":15250,"derivative":{"exercise_price":1.98,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":15250},"source":{"system":"sec-edgar","filing":"0001777631-26-000005","document":"wk-form4_1782170028.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777631/000177763126000005/wk-form4_1782170028.xml","form_type":"4"}},{"id":730520,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":308,"kind":"person","name":"WILSON KAREN J","position":1,"cik":"0001267490","reported_name":"WILSON KAREN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-22T23:13:21.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":15250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":15250,"derivative":{"exercise_price":1.98,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":15250},"source":{"system":"sec-edgar","filing":"0001267490-26-000008","document":"wk-form4_1782169998.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000126749026000008/wk-form4_1782169998.xml","form_type":"4"}},{"id":730774,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":36410,"kind":"person","name":"Marshall Richard Peter","position":1,"cik":"0002016188","reported_name":"Marshall Richard Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-22T23:12:52.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":15250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":15250,"derivative":{"exercise_price":1.98,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":15250},"source":{"system":"sec-edgar","filing":"0002016188-26-000004","document":"wk-form4_1782169969.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016188/000201618826000004/wk-form4_1782169969.xml","form_type":"4"}},{"id":737827,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":308,"kind":"person","name":"WILSON KAREN J","position":1,"cik":"0001267490","reported_name":"WILSON KAREN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-15T14:31:49.000Z","date":"2026-06-12","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":1.77,"value":8850.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.76 per share to a high purchase price of $1.77 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price."}],"balance_after":10100,"source":{"system":"sec-edgar","filing":"0001267490-26-000006","document":"wk-form4_1781533906.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000126749026000006/wk-form4_1781533906.xml","form_type":"4"}},{"id":737826,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":308,"kind":"person","name":"WILSON KAREN J","position":1,"cik":"0001267490","reported_name":"WILSON KAREN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-15T14:31:49.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":5100,"price":1.745,"value":8899.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.745 per share to a high purchase price of $1.75 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price."}],"balance_after":5100,"source":{"system":"sec-edgar","filing":"0001267490-26-000006","document":"wk-form4_1781533906.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000126749026000006/wk-form4_1781533906.xml","form_type":"4"}},{"id":762583,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":43932,"kind":"person","name":"LEDGER STEVEN A","position":1,"cik":"0001090206","reported_name":"LEDGER STEVEN A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-27T19:55:18.000Z","date":"2026-05-26","kind":"grant","planned":false,"acquired":true,"shares":10100,"price":1.93,"value":19493.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.87 per share to a high purchase price of $1.95 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price."}],"balance_after":10100,"source":{"system":"sec-edgar","filing":"0001090206-26-000007","document":"wk-form4_1779911715.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1090206/000109020626000007/wk-form4_1779911715.xml","form_type":"4"}},{"id":764113,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44295,"kind":"person","name":"Tenjarla Srini","position":1,"cik":"0002029985","reported_name":"Tenjarla Srini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CMC & Formulation"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T23:44:43.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":85558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested."}],"balance_after":85558,"derivative":{"exercise_price":1.89,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":85558},"source":{"system":"sec-edgar","filing":"0002029985-26-000004","document":"wk-form4_1779839080.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2029985/000202998526000004/wk-form4_1779839080.xml","form_type":"4"}},{"id":764436,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":43932,"kind":"person","name":"LEDGER STEVEN A","position":1,"cik":"0001090206","reported_name":"LEDGER STEVEN A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T23:37:17.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":380825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested."}],"balance_after":380825,"derivative":{"exercise_price":1.89,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":380825},"source":{"system":"sec-edgar","filing":"0001090206-26-000005","document":"wk-form4_1779838635.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1090206/000109020626000005/wk-form4_1779838635.xml","form_type":"4"}},{"id":763822,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44236,"kind":"person","name":"CURHAN GREGORY S","position":1,"cik":"0001263244","reported_name":"CURHAN GREGORY S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T23:35:30.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":123019,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested."}],"balance_after":123019,"derivative":{"exercise_price":1.89,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":123019},"source":{"system":"sec-edgar","filing":"0001263244-26-000002","document":"wk-form4_1779838527.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000126324426000002/wk-form4_1779838527.xml","form_type":"4"}},{"id":763821,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T23:33:30.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":85558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of\nthe shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested."}],"balance_after":85558,"derivative":{"exercise_price":1.89,"expiration_date":"2036-05-21","underlying":"Common Stock","underlying_shares":85558},"source":{"system":"sec-edgar","filing":"0001301120-26-000021","document":"wk-form4_1779838407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000021/wk-form4_1779838407.xml","form_type":"4"}},{"id":763820,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":308,"kind":"person","name":"WILSON KAREN J","position":1,"cik":"0001267490","reported_name":"WILSON KAREN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-26T20:26:47.000Z","date":"2026-05-22","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.93,"value":19300.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.90 per share to a high purchase price of $1.95 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001267490-26-000004","document":"wk-form4_1779827204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000126749026000004/wk-form4_1779827204.xml","form_type":"4"}},{"id":763819,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":308,"kind":"person","name":"WILSON KAREN J","position":1,"cik":"0001267490","reported_name":"WILSON KAREN J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-26T20:26:47.000Z","date":"2026-05-21","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.77,"value":17700.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.76 per share to a high purchase price of $1.79 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001267490-26-000004","document":"wk-form4_1779827204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000126749026000004/wk-form4_1779827204.xml","form_type":"4"}},{"id":766302,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":36410,"kind":"person","name":"Marshall Richard Peter","position":1,"cik":"0002016188","reported_name":"Marshall Richard Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-22T20:59:44.000Z","date":"2026-05-19","kind":"purchase","planned":false,"acquired":true,"shares":12183,"price":1.65,"value":20101.95,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.59 per share to a high purchase price of $1.73 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price."}],"balance_after":12183,"source":{"system":"sec-edgar","filing":"0002016188-26-000002","document":"wk-form4_1779483581.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2016188/000201618826000002/wk-form4_1779483581.xml","form_type":"4"}},{"id":803732,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":36340,"kind":"person","name":"Bailey Gregory","position":1,"cik":"0001329505","reported_name":"Bailey Gregory","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T19:45:42.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":59667,"price":1.94,"value":115753.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of common stock were issued for payment of accrued dividends on the reporting individuals Series A Convertible Preferred Stock issued on April 8, 2025."}],"balance_after":126910,"source":{"system":"sec-edgar","filing":"0001329505-26-000002","document":"wk-form4_1776800739.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000132950526000002/wk-form4_1776800739.xml","form_type":"4"}},{"id":803731,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":300,"kind":"person","name":"Venkatesan Jay","position":1,"cik":"0001413350","reported_name":"Venkatesan Jay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T19:31:50.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":7553,"price":1.94,"value":14652.82,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of common stock were issued for payment of accrued dividends on the reporting individuals A Convertible Preferred Stock issued on April 8, 2025."}],"balance_after":7553,"source":{"system":"sec-edgar","filing":"0001413350-26-000002","document":"wk-form4_1776799907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000141335026000002/wk-form4_1776799907.xml","form_type":"4"}},{"id":829388,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-24T23:24:24.000Z","date":"2026-03-23","kind":"exercise","planned":true,"acquired":false,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":267686,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001301120-26-000018","document":"wk-form4_1774394662.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000018/wk-form4_1774394662.xml","form_type":"4"}},{"id":829387,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-24T23:24:24.000Z","date":"2026-03-23","kind":"sale","planned":true,"acquired":false,"shares":6500,"price":2.8566,"value":18567.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"1. The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.68 to $3.03. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-26-000018","document":"wk-form4_1774394662.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000018/wk-form4_1774394662.xml","form_type":"4"}},{"id":829386,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-24T23:24:24.000Z","date":"2026-03-23","kind":"exercise","planned":true,"acquired":true,"shares":6500,"price":0.06,"value":390.0,"ownership":{"direct":true},"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001301120-26-000018","document":"wk-form4_1774394662.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000018/wk-form4_1774394662.xml","form_type":"4"}},{"id":832379,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-20T18:20:45.000Z","date":"2026-03-19","kind":"exercise","planned":true,"acquired":false,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options are fully vested."}],"balance_after":274186,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001301120-26-000016","document":"wk-form4_1774030842.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000016/wk-form4_1774030842.xml","form_type":"4"}},{"id":832378,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-20T18:20:45.000Z","date":"2026-03-19","kind":"sale","planned":true,"acquired":false,"shares":39000,"price":2.5,"value":97500.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-26-000016","document":"wk-form4_1774030842.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000016/wk-form4_1774030842.xml","form_type":"4"}},{"id":832377,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-20T18:20:45.000Z","date":"2026-03-19","kind":"exercise","planned":true,"acquired":true,"shares":39000,"price":0.06,"value":2340.0,"ownership":{"direct":true},"balance_after":39000,"source":{"system":"sec-edgar","filing":"0001301120-26-000016","document":"wk-form4_1774030842.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000016/wk-form4_1774030842.xml","form_type":"4"}},{"id":901083,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-17T13:35:57.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":69000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested."}],"balance_after":69000,"derivative":{"exercise_price":2.76,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":69000},"source":{"system":"sec-edgar","filing":"0001301120-26-000014","document":"wk-form4_1771335355.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000014/wk-form4_1771335355.xml","form_type":"4"}},{"id":901446,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44295,"kind":"person","name":"Tenjarla Srini","position":1,"cik":"0002029985","reported_name":"Tenjarla Srini","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CMC & Formulation"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-17T13:29:18.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":69000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested."}],"balance_after":69000,"derivative":{"exercise_price":2.76,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":69000},"source":{"system":"sec-edgar","filing":"0002029985-26-000002","document":"wk-form4_1771334956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2029985/000202998526000002/wk-form4_1771334956.xml","form_type":"4"}},{"id":901270,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":35426,"kind":"person","name":"GILL SIMBA","position":1,"cik":"0001180763","reported_name":"GILL SIMBA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-17T13:24:46.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":92000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested."}],"balance_after":92000,"derivative":{"exercise_price":2.76,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":92000},"source":{"system":"sec-edgar","filing":"0001180763-26-000002","document":"wk-form4_1771334683.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180763/000118076326000002/wk-form4_1771334683.xml","form_type":"4"}},{"id":902003,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":43932,"kind":"person","name":"LEDGER STEVEN A","position":1,"cik":"0001090206","reported_name":"LEDGER STEVEN A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-17T13:20:35.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":230100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested."}],"balance_after":230100,"derivative":{"exercise_price":2.76,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":230100},"source":{"system":"sec-edgar","filing":"0001090206-26-000003","document":"wk-form4_1771334433.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1090206/000109020626000003/wk-form4_1771334433.xml","form_type":"4"}},{"id":921941,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-03T17:35:37.000Z","date":"2026-02-02","kind":"exercise","planned":true,"acquired":false,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":313186,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001301120-26-000012","document":"wk-form4_1770140133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000012/wk-form4_1770140133.xml","form_type":"4"}},{"id":921940,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-03T17:35:37.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":6500,"price":3.0277,"value":19680.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.00. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-26-000012","document":"wk-form4_1770140133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000012/wk-form4_1770140133.xml","form_type":"4"}},{"id":921939,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-03T17:35:37.000Z","date":"2026-02-02","kind":"exercise","planned":true,"acquired":true,"shares":6500,"price":0.06,"value":390.0,"ownership":{"direct":true},"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001301120-26-000012","document":"wk-form4_1770140133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000012/wk-form4_1770140133.xml","form_type":"4"}},{"id":927911,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-29T17:54:00.000Z","date":"2026-01-28","kind":"exercise","planned":true,"acquired":false,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":319686,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001301120-26-000010","document":"wk-form4_1769709237.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000010/wk-form4_1769709237.xml","form_type":"4"}},{"id":927910,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-29T17:54:00.000Z","date":"2026-01-28","kind":"sale","planned":true,"acquired":false,"shares":6500,"price":3.567,"value":23185.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.59 to $3.55. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-26-000010","document":"wk-form4_1769709237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000010/wk-form4_1769709237.xml","form_type":"4"}},{"id":927909,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-29T17:54:00.000Z","date":"2026-01-28","kind":"exercise","planned":true,"acquired":true,"shares":6500,"price":0.06,"value":390.0,"ownership":{"direct":true},"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001301120-26-000010","document":"wk-form4_1769709237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000010/wk-form4_1769709237.xml","form_type":"4"}},{"id":932318,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-23T17:35:09.000Z","date":"2026-01-22","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options are fully vested."}],"balance_after":326186,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001301120-26-000008","document":"wk-form4_1769189706.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000008/wk-form4_1769189706.xml","form_type":"4"}},{"id":932317,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-23T17:35:09.000Z","date":"2026-01-22","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":2.95,"value":7375.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-26-000008","document":"wk-form4_1769189706.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000008/wk-form4_1769189706.xml","form_type":"4"}},{"id":932316,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-23T17:35:09.000Z","date":"2026-01-22","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":0.06,"value":150.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001301120-26-000008","document":"wk-form4_1769189706.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000008/wk-form4_1769189706.xml","form_type":"4"}},{"id":934235,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-22T00:17:14.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options are fully vested."}],"balance_after":328686,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001301120-26-000006","document":"wk-form4_1769041031.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000006/wk-form4_1769041031.xml","form_type":"4"}},{"id":934234,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-22T00:17:14.000Z","date":"2026-01-20","kind":"exercise","planned":true,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options are fully vested."}],"balance_after":330686,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001301120-26-000006","document":"wk-form4_1769041031.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000006/wk-form4_1769041031.xml","form_type":"4"}},{"id":934233,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-22T00:17:14.000Z","date":"2026-01-21","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":3,"value":6000.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-26-000006","document":"wk-form4_1769041031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000006/wk-form4_1769041031.xml","form_type":"4"}},{"id":934232,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-22T00:17:14.000Z","date":"2026-01-21","kind":"exercise","planned":true,"acquired":true,"shares":2000,"price":0.06,"value":120.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001301120-26-000006","document":"wk-form4_1769041031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000006/wk-form4_1769041031.xml","form_type":"4"}},{"id":934231,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-22T00:17:14.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":3.07,"value":6140.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-26-000006","document":"wk-form4_1769041031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000006/wk-form4_1769041031.xml","form_type":"4"}},{"id":934230,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-22T00:17:14.000Z","date":"2026-01-20","kind":"exercise","planned":true,"acquired":true,"shares":2000,"price":0.06,"value":120.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001301120-26-000006","document":"wk-form4_1769041031.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000006/wk-form4_1769041031.xml","form_type":"4"}},{"id":939227,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-14T17:56:48.000Z","date":"2026-01-14","kind":"exercise","planned":true,"acquired":false,"shares":1084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":332686,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":1084},"source":{"system":"sec-edgar","filing":"0001301120-26-000004","document":"wk-form4_1768413405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000004/wk-form4_1768413405.xml","form_type":"4"}},{"id":939226,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-14T17:56:48.000Z","date":"2026-01-13","kind":"exercise","planned":true,"acquired":false,"shares":5416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":333770,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":5416},"source":{"system":"sec-edgar","filing":"0001301120-26-000004","document":"wk-form4_1768413405.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000004/wk-form4_1768413405.xml","form_type":"4"}},{"id":939225,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-14T17:56:48.000Z","date":"2026-01-14","kind":"sale","planned":true,"acquired":false,"shares":1084,"price":2.5031,"value":2713.3604,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.54 to $2.50. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-26-000004","document":"wk-form4_1768413405.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000004/wk-form4_1768413405.xml","form_type":"4"}},{"id":939224,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-14T17:56:48.000Z","date":"2026-01-14","kind":"exercise","planned":true,"acquired":true,"shares":1084,"price":0.06,"value":65.04,"ownership":{"direct":true},"balance_after":1084,"source":{"system":"sec-edgar","filing":"0001301120-26-000004","document":"wk-form4_1768413405.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000004/wk-form4_1768413405.xml","form_type":"4"}},{"id":939223,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-14T17:56:48.000Z","date":"2026-01-13","kind":"sale","planned":true,"acquired":false,"shares":5416,"price":2.5,"value":13540.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-26-000004","document":"wk-form4_1768413405.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000004/wk-form4_1768413405.xml","form_type":"4"}},{"id":939222,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-14T17:56:48.000Z","date":"2026-01-13","kind":"exercise","planned":true,"acquired":true,"shares":5416,"price":0.06,"value":324.96,"ownership":{"direct":true},"balance_after":5416,"source":{"system":"sec-edgar","filing":"0001301120-26-000004","document":"wk-form4_1768413405.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000004/wk-form4_1768413405.xml","form_type":"4"}},{"id":942146,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-09T17:27:30.000Z","date":"2026-01-08","kind":"exercise","planned":true,"acquired":false,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":339186,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001301120-26-000002","document":"wk-form4_1767979647.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000002/wk-form4_1767979647.xml","form_type":"4"}},{"id":942145,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-09T17:27:30.000Z","date":"2026-01-08","kind":"sale","planned":true,"acquired":false,"shares":13000,"price":2.6887,"value":34953.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $2.60. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $2.60. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-26-000002","document":"wk-form4_1767979647.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000002/wk-form4_1767979647.xml","form_type":"4"}},{"id":942144,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-09T17:27:30.000Z","date":"2026-01-08","kind":"exercise","planned":true,"acquired":true,"shares":13000,"price":0.06,"value":780.0,"ownership":{"direct":true},"balance_after":13000,"source":{"system":"sec-edgar","filing":"0001301120-26-000002","document":"wk-form4_1767979647.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112026000002/wk-form4_1767979647.xml","form_type":"4"}},{"id":958229,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-29T16:40:10.000Z","date":"2025-12-23","kind":"exercise","planned":true,"acquired":false,"shares":4100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options are fully vested."}],"balance_after":352186,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":4100},"source":{"system":"sec-edgar","filing":"0001301120-25-000039","document":"wk-form4_1767026407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000039/wk-form4_1767026407.xml","form_type":"4"}},{"id":958228,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-29T16:40:10.000Z","date":"2025-12-23","kind":"sale","planned":true,"acquired":false,"shares":4100,"price":2.6,"value":10660.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-25-000039","document":"wk-form4_1767026407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000039/wk-form4_1767026407.xml","form_type":"4"}},{"id":958227,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-29T16:40:10.000Z","date":"2025-12-23","kind":"exercise","planned":true,"acquired":true,"shares":4100,"price":0.06,"value":246.0,"ownership":{"direct":true},"balance_after":4100,"source":{"system":"sec-edgar","filing":"0001301120-25-000039","document":"wk-form4_1767026407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000039/wk-form4_1767026407.xml","form_type":"4"}},{"id":959666,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-23T19:04:33.000Z","date":"2025-12-22","kind":"exercise","planned":true,"acquired":false,"shares":5673,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":356286,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":5673},"source":{"system":"sec-edgar","filing":"0001301120-25-000037","document":"wk-form4_1766516671.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000037/wk-form4_1766516671.xml","form_type":"4"}},{"id":959665,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-23T19:04:33.000Z","date":"2025-12-22","kind":"sale","planned":true,"acquired":false,"shares":5673,"price":2.6737,"value":15167.9001,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.705 to $2.66. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-25-000037","document":"wk-form4_1766516671.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000037/wk-form4_1766516671.xml","form_type":"4"}},{"id":959664,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-23T19:04:33.000Z","date":"2025-12-22","kind":"exercise","planned":true,"acquired":true,"shares":5673,"price":0.06,"value":340.38,"ownership":{"direct":true},"balance_after":5673,"source":{"system":"sec-edgar","filing":"0001301120-25-000037","document":"wk-form4_1766516671.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000037/wk-form4_1766516671.xml","form_type":"4"}},{"id":965079,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-18T00:56:57.000Z","date":"2025-12-16","kind":"exercise","planned":true,"acquired":false,"shares":3227,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":361959,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":3227},"source":{"system":"sec-edgar","filing":"0001301120-25-000035","document":"wk-form4_1766019414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000035/wk-form4_1766019414.xml","form_type":"4"}},{"id":965078,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-18T00:56:57.000Z","date":"2025-12-16","kind":"sale","planned":true,"acquired":false,"shares":3227,"price":2.9631,"value":9561.9237,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $2.96. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-25-000035","document":"wk-form4_1766019414.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000035/wk-form4_1766019414.xml","form_type":"4"}},{"id":965077,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-18T00:56:57.000Z","date":"2025-12-16","kind":"exercise","planned":true,"acquired":true,"shares":3227,"price":0.06,"value":193.62,"ownership":{"direct":true},"balance_after":3227,"source":{"system":"sec-edgar","filing":"0001301120-25-000035","document":"wk-form4_1766019414.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000035/wk-form4_1766019414.xml","form_type":"4"}},{"id":967605,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-16T23:59:24.000Z","date":"2025-12-12","kind":"exercise","planned":true,"acquired":false,"shares":1700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":365186,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":1700},"source":{"system":"sec-edgar","filing":"0001301120-25-000033","document":"wk-form4_1765929561.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000033/wk-form4_1765929561.xml","form_type":"4"}},{"id":967604,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-16T23:59:24.000Z","date":"2025-12-12","kind":"sale","planned":true,"acquired":false,"shares":1700,"price":3.2597,"value":5541.49,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.275. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-25-000033","document":"wk-form4_1765929561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000033/wk-form4_1765929561.xml","form_type":"4"}},{"id":967603,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-16T23:59:24.000Z","date":"2025-12-12","kind":"exercise","planned":true,"acquired":true,"shares":1700,"price":0.06,"value":102.0,"ownership":{"direct":true},"balance_after":1700,"source":{"system":"sec-edgar","filing":"0001301120-25-000033","document":"wk-form4_1765929561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000033/wk-form4_1765929561.xml","form_type":"4"}},{"id":971253,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-12T17:48:08.000Z","date":"2025-12-11","kind":"exercise","planned":true,"acquired":false,"shares":3555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":366886,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":3555},"source":{"system":"sec-edgar","filing":"0001301120-25-000030","document":"wk-form4_1765561686.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000030/wk-form4_1765561686.xml","form_type":"4"}},{"id":971252,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-12T17:48:08.000Z","date":"2025-12-11","kind":"sale","planned":true,"acquired":false,"shares":3555,"price":3.2404,"value":11519.622,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 to $3.35. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-25-000030","document":"wk-form4_1765561686.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000030/wk-form4_1765561686.xml","form_type":"4"}},{"id":971251,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-12T17:48:08.000Z","date":"2025-12-11","kind":"exercise","planned":true,"acquired":true,"shares":3555,"price":0.06,"value":213.3,"ownership":{"direct":true},"balance_after":3555,"source":{"system":"sec-edgar","filing":"0001301120-25-000030","document":"wk-form4_1765561686.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000030/wk-form4_1765561686.xml","form_type":"4"}},{"id":972678,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-11T21:11:24.000Z","date":"2025-12-10","kind":"exercise","planned":true,"acquired":false,"shares":645,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":370441,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":645},"source":{"system":"sec-edgar","filing":"0001301120-25-000027","document":"wk-form4_1765487480.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000027/wk-form4_1765487480.xml","form_type":"4"}},{"id":972677,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-11T21:11:24.000Z","date":"2025-12-09","kind":"exercise","planned":true,"acquired":false,"shares":600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":371086,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":600},"source":{"system":"sec-edgar","filing":"0001301120-25-000027","document":"wk-form4_1765487480.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000027/wk-form4_1765487480.xml","form_type":"4"}},{"id":972676,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-11T21:11:24.000Z","date":"2025-12-10","kind":"sale","planned":true,"acquired":false,"shares":645,"price":3.35,"value":2160.75,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-25-000027","document":"wk-form4_1765487480.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000027/wk-form4_1765487480.xml","form_type":"4"}},{"id":972675,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-11T21:11:24.000Z","date":"2025-12-10","kind":"grant","planned":true,"acquired":true,"shares":645,"price":0.06,"value":38.7,"ownership":{"direct":true},"balance_after":645,"source":{"system":"sec-edgar","filing":"0001301120-25-000027","document":"wk-form4_1765487480.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000027/wk-form4_1765487480.xml","form_type":"4"}},{"id":972674,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-11T21:11:24.000Z","date":"2025-12-09","kind":"sale","planned":true,"acquired":false,"shares":600,"price":3.3133,"value":1987.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.31 to $3.315. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-25-000027","document":"wk-form4_1765487480.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000027/wk-form4_1765487480.xml","form_type":"4"}},{"id":972673,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-11T21:11:24.000Z","date":"2025-12-09","kind":"exercise","planned":true,"acquired":true,"shares":600,"price":0.06,"value":36.0,"ownership":{"direct":true},"balance_after":600,"source":{"system":"sec-edgar","filing":"0001301120-25-000027","document":"wk-form4_1765487480.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000027/wk-form4_1765487480.xml","form_type":"4"}},{"id":980337,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T00:56:00.000Z","date":"2025-12-03","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options are fully vested."}],"balance_after":371686,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001301120-25-000025","document":"wk-form4_1764896157.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000025/wk-form4_1764896157.xml","form_type":"4"}},{"id":980336,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T00:56:00.000Z","date":"2025-12-02","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options are fully vested."}],"balance_after":376686,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001301120-25-000025","document":"wk-form4_1764896157.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000025/wk-form4_1764896157.xml","form_type":"4"}},{"id":980335,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-05T00:56:00.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":3.5246,"value":17623.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.47 to $3.55. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.47 to $3.55. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-25-000025","document":"wk-form4_1764896157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000025/wk-form4_1764896157.xml","form_type":"4"}},{"id":980334,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-05T00:56:00.000Z","date":"2025-12-03","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":0.06,"value":300.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001301120-25-000025","document":"wk-form4_1764896157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000025/wk-form4_1764896157.xml","form_type":"4"}},{"id":980333,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-05T00:56:00.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":3.9052,"value":5857.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.9112. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-25-000025","document":"wk-form4_1764896157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000025/wk-form4_1764896157.xml","form_type":"4"}},{"id":980332,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-05T00:56:00.000Z","date":"2025-12-02","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":0.06,"value":90.0,"ownership":{"direct":true},"balance_after":1500,"source":{"system":"sec-edgar","filing":"0001301120-25-000025","document":"wk-form4_1764896157.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000025/wk-form4_1764896157.xml","form_type":"4"}},{"id":987019,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-26T22:21:54.000Z","date":"2025-11-25","kind":"exercise","planned":true,"acquired":false,"shares":5965,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":378186,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":5965},"source":{"system":"sec-edgar","filing":"0001301120-25-000023","document":"wk-form4_1764195711.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000023/wk-form4_1764195711.xml","form_type":"4"}},{"id":987018,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-11-26T22:21:54.000Z","date":"2025-11-25","kind":"sale","planned":true,"acquired":false,"shares":5965,"price":3.9001,"value":23264.0965,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.91. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":5965,"source":{"system":"sec-edgar","filing":"0001301120-25-000023","document":"wk-form4_1764195711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000023/wk-form4_1764195711.xml","form_type":"4"}},{"id":987017,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-11-26T22:21:54.000Z","date":"2025-11-25","kind":"exercise","planned":true,"acquired":true,"shares":5965,"price":0.06,"value":357.9,"ownership":{"direct":true},"balance_after":11930,"source":{"system":"sec-edgar","filing":"0001301120-25-000023","document":"wk-form4_1764195711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000023/wk-form4_1764195711.xml","form_type":"4"}},{"id":988728,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-26T02:20:06.000Z","date":"2025-11-24","kind":"exercise","planned":true,"acquired":false,"shares":535,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":384151,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":535},"source":{"system":"sec-edgar","filing":"0001628280-25-054059","document":"wk-form4_1764123603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000162828025054059/wk-form4_1764123603.xml","form_type":"4"}},{"id":988727,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-11-26T02:20:06.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":535,"price":3.935,"value":2105.225,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.98 to $3.917. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-25-054059","document":"wk-form4_1764123603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000162828025054059/wk-form4_1764123603.xml","form_type":"4"}},{"id":988726,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-11-26T02:20:06.000Z","date":"2025-11-24","kind":"exercise","planned":true,"acquired":true,"shares":535,"price":0.06,"value":32.1,"ownership":{"direct":true},"balance_after":535,"source":{"system":"sec-edgar","filing":"0001628280-25-054059","document":"wk-form4_1764123603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000162828025054059/wk-form4_1764123603.xml","form_type":"4"}},{"id":993862,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-19T18:47:46.000Z","date":"2025-11-18","kind":"exercise","planned":true,"acquired":false,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":384686,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001301120-25-000021","document":"wk-form4_1763578063.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000021/wk-form4_1763578063.xml","form_type":"4"}},{"id":993861,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-11-19T18:47:46.000Z","date":"2025-11-18","kind":"sale","planned":true,"acquired":false,"shares":6500,"price":3.7541,"value":24401.65,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.71. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-25-000021","document":"wk-form4_1763578063.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000021/wk-form4_1763578063.xml","form_type":"4"}},{"id":993860,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-11-19T18:47:46.000Z","date":"2025-11-18","kind":"exercise","planned":true,"acquired":true,"shares":6500,"price":0.06,"value":390.0,"ownership":{"direct":true},"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001301120-25-000021","document":"wk-form4_1763578063.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000021/wk-form4_1763578063.xml","form_type":"4"}},{"id":1002053,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-12T17:38:16.000Z","date":"2025-11-10","kind":"exercise","planned":true,"acquired":false,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested."}],"balance_after":391186,"derivative":{"exercise_price":0.06,"expiration_date":"2031-05-06","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001301120-25-000019","document":"wk-form4_1762969093.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000019/wk-form4_1762969093.xml","form_type":"4"}},{"id":1002052,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-11-12T17:38:16.000Z","date":"2025-11-10","kind":"sale","planned":true,"acquired":false,"shares":6500,"price":4.1,"value":26650.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.00. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001301120-25-000019","document":"wk-form4_1762969093.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000019/wk-form4_1762969093.xml","form_type":"4"}},{"id":1002051,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":44235,"kind":"person","name":"Moreadith Randall","position":1,"cik":"0001301120","reported_name":"Moreadith Randall","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-11-12T17:38:16.000Z","date":"2025-11-10","kind":"exercise","planned":true,"acquired":true,"shares":6500,"price":0.06,"value":390.0,"ownership":{"direct":true},"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001301120-25-000019","document":"wk-form4_1762969093.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1708599/000130112025000019/wk-form4_1762969093.xml","form_type":"4"}},{"id":1003789,"issuer":{"id":9581,"kind":"organization","name":"Serina Therapeutics, Inc."},"owners":[{"id":31223,"kind":"person","name":"Brannan Stephen K.","position":1,"cik":"0001777631","reported_name":"Brannan Stephen K.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-11T01:09:47.000Z","date":"2025-11-07","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":10000,"derivative":{"exercise_price":3.91,"expiration_date":"2035-11-07","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001708599-25-000128","document":"wk-form4_1762823384.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1777631/000170859925000128/wk-form4_1762823384.xml","form_type":"4"}}],"next_cursor":"2025-11-11T01:09:47.000000Z,1003789"}